Age-related macular degeneration Eye Diseases
Conditions
Interventions
Between May 2014 and May 2015, 180 patients were randomly collected in a 1:1 ratio for treatments using conbercept or ranibizumab (n=90 in each cohort) from these four centers. These patients were ran
Sponsors
The First Hospital of Qiqihar City
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 51–85 years 2. Previously untreated active neovascular AMD in one eye 3. Absence of other ocular diseases determined by examination using a tonometer, slit lamp biomicroscope and ophthalmoscope 4. Lack of polypoidal choroidal vasculopathy (PCV) as determined by indocyanine green angiography (ICGA) 5. Total area of the subretinal hemorrhage and fibrosis comprised less than 50% of the total lesion
Exclusion criteria
Exclusion criteria: 1. Other serious illness 2. Systematic diseases 3. Polypoidal choroidal vasculopathy (PCV) 4. Subretinal hemorrhage and fibrosis comprised more than 50% of the total lesion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity (BCVA), as determined using the ETDRS chart at one year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The number of injections counted at the end of one year follow-up 2. Retinal thickness measured at every visit by OCT 3. Leakage of CNV measured at every visit by fundus fluorescein angiography (FFA) 4. Ocular complications measured at every visit by ophthalmologist examination | — |
Countries
China
Outcome results
None listed